Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and immunogenicity of collagenase clostridium histolyticum in Peyronie's disease
2014-004239-37Phase 4Completed
- Sponsor
- Auxilium UK Limited
- Start
- Nov 2014
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of collagenase clostridium histolyticum in Peyronie's disease, sponsored by Auxilium UK Limited. Primary endpoints: Curvature deformity measurements, Safety over time and 1 more. Started Nov 2014; status: completed.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
Peyronie's disease
Beyond the preview
Go deeper on 2014-004239-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004239-37.